Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Reddit Post Question

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 01, 2021 9:05pm

98 Views

Post# 32691943

RE:RE:RE:RE:Reddit Post Question

I posted an article published recently which stated the focus has been shifted from BMI to visceral fat.
There are many studies regarding lean NAFLD so weight loss only wouldn't necessarily stop the disease.
That's the idea behind renaming NAFLD to MAFLD.
The metabolic issues are getting more recognition as the causation of the condition.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale